Healthcare & Life Sciences
eTheRNA Immunotherapies
Belgium
series-b
series-b
Stage
1
Investors
About
eTheRNA Immunotherapies is a clinical-stage biotechnology company developing mRNA-based immunotherapies for cancer using its proprietary TriMix platform, which activates dendritic cells to induce antigen-specific T-cell responses against tumors.
Explore eTheRNA Immunotherapies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.